Literature DB >> 23625637

Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells.

Tong-Xin Xie1, Ge Zhou, Mei Zhao, Daisuke Sano, Samar A Jasser, Richard G Brennan, Jeffrey N Myers.   

Abstract

OBJECTIVES/HYPOTHESIS: Mutation of the TP53 gene occurs in more than half of cases of head and neck squamous cell carcinoma (HNSCC). However, little is known about how specific TP53 mutations affect tumor progression. The objective of this study is to determine the gain of function of mutant p53 with a proline-to-serine substitution at codon 151. STUDY
DESIGN: Laboratory-based study.
METHODS: A panel of HNSCC cell lines was determined with anoikis assays, and orthotopic mouse experiments were performed. TP53 was sequenced. The shRNA knockdown and overexpression approaches were used for testing mutant p53 functions. The crystal structure of the p53 protein was analyzed using an in silico approach.
RESULTS: An anoikis-resistant cell line, Tu138, was found to have a proline-to-serine substitution at codon 151 of TP53, which results in loss of wild-type p53 transcriptional activity. Moreover, the mutant p53 was shown to promote anoikis resistance and soft agar growth. Using an in silico approach based on the crystal structure of wild-type p53 protein, substitution of proline by serine at position 151 would create a cavity in a hydrophobic pocket, the loss of van der Waals contacts, and the thermodynamically unfavorable placement of a polar group, the hydroxyl oxygen atom of the serine, within a hydrophobic region, all of which likely cause a locally altered structure.
CONCLUSIONS: Our data suggest that mutation at position 151 leads to a structural alteration, which results in significant functional changes in the p53 protein that impact tumor progression.
Copyright © 2012 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23625637      PMCID: PMC3664100          DOI: 10.1002/lary.23846

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  31 in total

Review 1.  p53 and human cancer: the first ten thousand mutations.

Authors:  P Hainaut; M Hollstein
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

2.  An orthotopic nude mouse model of oral tongue squamous cell carcinoma.

Authors:  Jeffrey N Myers; F Christopher Holsinger; Samar A Jasser; B Nebiyou Bekele; Isaiah J Fidler
Journal:  Clin Cancer Res       Date:  2002-01       Impact factor: 12.531

Review 3.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

Authors:  A Sigal; V Rotter
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

Review 4.  Rescuing the function of mutant p53.

Authors:  A N Bullock; A R Fersht
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

5.  The IARC TP53 database: new online mutation analysis and recommendations to users.

Authors:  Magali Olivier; Ros Eeles; Monica Hollstein; Mohammed A Khan; Curtis C Harris; Pierre Hainaut
Journal:  Hum Mutat       Date:  2002-06       Impact factor: 4.878

6.  Complex functions of mutant p53 alleles from human prostate cancer.

Authors:  Xu-Bao Shi; Nancy J Nesslinger; Arline D Deitch; Paul H Gumerlock; Ralph W deVere White
Journal:  Prostate       Date:  2002-04-01       Impact factor: 4.104

Review 7.  TP53 and head and neck neoplasms.

Authors:  Hélène Blons; Pierre Laurent-Puig
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

8.  Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.

Authors:  Nancy J Nesslinger; Xu-Bao Shi; Ralph W deVere White
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

9.  Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.

Authors:  Shunsuke Kato; Shuang-Yin Han; Wen Liu; Kazunori Otsuka; Hiroyuki Shibata; Ryunosuke Kanamaru; Chikashi Ishioka
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 11.205

10.  Acquisition of anoikis resistance is a critical step in the progression of oral tongue cancer.

Authors:  Eric A Swan; Samar A Jasser; Floyd C Holsinger; Dao Doan; Cora Bucana; Jeffrey N Myers
Journal:  Oral Oncol       Date:  2003-10       Impact factor: 5.337

View more
  11 in total

1.  The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis.

Authors:  Siddharth Singh; Manoj Kumar; Sanjeev Kumar; Shrinka Sen; Pawan Upadhyay; Sayan Bhattacharjee; Naveen M; Vivek Singh Tomar; Siddhartha Roy; Amit Dutt; Tapas K Kundu
Journal:  J Biol Chem       Date:  2019-07-31       Impact factor: 5.157

Review 2.  TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.

Authors:  Ge Zhou; Zhiyi Liu; Jeffrey N Myers
Journal:  J Cell Biochem       Date:  2016-06-03       Impact factor: 4.429

3.  Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.

Authors:  David M Neskey; Abdullah A Osman; Thomas J Ow; Panagiotis Katsonis; Thomas McDonald; Stephanie C Hicks; Teng-Kuei Hsu; Curtis R Pickering; Alexandra Ward; Ameeta Patel; John S Yordy; Heath D Skinner; Uma Giri; Daisuke Sano; Michael D Story; Beth M Beadle; Adel K El-Naggar; Merrill S Kies; William N William; Carlos Caulin; Mitchell Frederick; Marek Kimmel; Jeffrey N Myers; Olivier Lichtarge
Journal:  Cancer Res       Date:  2015-01-29       Impact factor: 12.701

Review 4.  Targeting the DNA Damage Response in OSCC with TP53 Mutations.

Authors:  A Lindemann; H Takahashi; A A Patel; A A Osman; J N Myers
Journal:  J Dent Res       Date:  2018-02-28       Impact factor: 6.116

5.  TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.

Authors:  Pavla Brachova; Samuel R Mueting; Matthew J Carlson; Michael J Goodheart; Anna M Button; Sarah L Mott; Donghai Dai; Kristina W Thiel; Eric J Devor; Kimberly K Leslie
Journal:  Int J Oncol       Date:  2014-11-11       Impact factor: 5.650

6.  Oncomorphic TP53 Mutations in Gynecologic Cancers Lose the Normal Protein:Protein Interactions with the microRNA Microprocessing Complex.

Authors:  Pavla Brachova; Samuel R Mueting; Eric J Devor; Kimberly K Leslie
Journal:  J Cancer Ther       Date:  2014-06-01

7.  Activation of Casein Kinase II by Gallic Acid Induces BIK-BAX/BAK-Mediated ER Ca++-ROS-Dependent Apoptosis of Human Oral Cancer Cells.

Authors:  Meng-Liang Lin; Shih-Shun Chen
Journal:  Front Physiol       Date:  2017-09-29       Impact factor: 4.566

8.  Docosahexaenoic acid inhibits the proliferation of Kras/TP53 double mutant pancreatic ductal adenocarcinoma cells through modulation of glutathione level and suppression of nucleotide synthesis.

Authors:  Wei-Chia Hung; Der-Yen Lee; En-Pei Isabel Chiang; Jia-Ning Syu; Che-Yi Chao; Mei-Due Yang; Shu-Yao Tsai; Feng-Yao Tang
Journal:  PLoS One       Date:  2020-11-02       Impact factor: 3.240

Review 9.  Mutant p53 in cancer: new functions and therapeutic opportunities.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

Review 10.  Molecular crosstalk between cancer and neurodegenerative diseases.

Authors:  Jiyeon Seo; Mikyoung Park
Journal:  Cell Mol Life Sci       Date:  2019-12-28       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.